Drug Profile
Research programme: bispecific and trispecific antibodies - Covagen
Alternative Names: Bispecific FynomAbs - Covagen; COVA-208; COVA-4231; FynomAbs - Covagen; Polyspecific FynomAbs - Covagen; Trispecific FynomAbs - CovagenLatest Information Update: 28 Apr 2020
Price :
$50
*
At a glance
- Originator Covagen
- Developer Covagen; Mitsubishi Tanabe Pharma Corporation; Tanabe Research Laboratories USA
- Class Bispecific antibodies; Trispecific antibodies
- Mechanism of Action Antibody-dependent cell cytotoxicity; Cytokine inhibitors; ERBB 2 receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes - Cancer; Inflammation
Highest Development Phases
- No development reported Ankylosing spondylitis; Cancer; Inflammation; Psoriasis; Psoriatic arthritis; Rheumatoid arthritis
Most Recent Events
- 28 Apr 2020 No recent reports of development identified for preclinical development in Ankylosing-spondylitis in Switzerland (Parenteral)
- 28 Apr 2020 No recent reports of development identified for preclinical development in Inflammation in Switzerland (Parenteral)
- 28 Apr 2020 No recent reports of development identified for preclinical development in Psoriasis in Switzerland (Parenteral)